Bank of America expects Novartis to use its upcoming capital markets day to raise its midterm growth target above what Wall Street is currently modeling, according to a research note from the bank. The event, scheduled for November 19, is likely to set a new baseline for the Swiss drugmaker's sales growth and outline how it plans to fill a revenue gap that emerges after key patents expire in the early 2030s.
What BofA expects
In its note, BofA Global Research said Novartis will probably roll its current midterm outlook forward, pointing to roughly 5% annual sales growth from 2026 through 2031. That compares with about 4% that analysts are currently modeling for the same period. The bank also expects management to maintain a "mid-single-digit" sales growth story beyond 2031, even though consensus forecasts for 2031-2033 imply a low-single-digit decline.
The gap between what Novartis says and what the market expects is significant. If the company delivers on its own guidance, it would beat the Street's numbers by a meaningful margin. That could support the stock, which has been under pressure in recent months as investors worry about the looming patent cliff.
Why the patent cliff matters
Novartis, like many large pharmaceutical companies, faces a period when several of its top-selling drugs lose patent protection. When that happens, cheaper generic competitors can enter the market, often causing a sharp drop in sales for the original drug. For Novartis, the early 2030s are seen as a critical window when this could hit hardest.
To offset that, the company needs new products to ramp up in time. BofA expects the capital markets day to highlight new pipeline drivers—drugs in development that could become blockbusters—and explain how they will help cover the post-2031 gap. This is a common strategy for pharma companies: they use investor days to showcase their pipeline and reassure shareholders that future growth is on the way.
Investors will be listening closely for specifics. Which drugs are furthest along? What are the potential peak sales? How confident is management in the timeline? These details can move the stock, as they give analysts a basis to update their models.
What it means for investors
For everyday investors, the key takeaway is that Novartis is signaling confidence in its ability to grow faster than the market currently expects. If the company delivers on that promise, it could mean stronger earnings and potentially a higher stock price over the medium term. But it's also a reminder that pharma stocks are heavily dependent on pipeline success and patent expirations—events that are hard to predict and can be volatile.
It's worth noting that BofA's view is just one bank's opinion. Other analysts may have different forecasts, and the actual guidance Novartis provides on November 19 could differ. Still, the note gives a useful preview of what to watch for.
Investors should also consider the broader context. The pharmaceutical sector has been under pressure from drug pricing debates, regulatory scrutiny, and competition from cheaper generics. Companies like Novartis are trying to navigate these headwinds while also investing in new therapies, often in areas like oncology, immunology, and gene therapy.
For those who own Novartis shares, the capital markets day is a chance to hear directly from management about the company's strategy and outlook. For those considering an investment, it's an opportunity to gauge whether the company's growth story is credible.
As always, it's important to remember that past performance is not a guarantee of future results, and any investment decision should be based on your own research and risk tolerance. This article is for informational purposes only and does not constitute financial advice.
In the meantime, investors can look at how other companies in the sector are positioning themselves. For example, UBS sees Haleon trimming its FY26 growth target, which shows that not all consumer health companies are as optimistic. Similarly, Reckitt's Q3 sales are seen up 3.7%, indicating steady but modest growth in the sector.
Novartis's capital markets day will be a key event for the stock, and BofA's note sets the stage for what could be a positive surprise. Whether the company meets, beats, or misses those expectations will be the next big test.
